Year: 2023
Type: article
Abstract: Colorectal cancer (CRC), one of the world's most prevalent and deadliest tumors, resulted in around 881,000 melanoma fatalities in 2018. Colorectal cancer (CRC) is the third-most common cause of all cancer-related deaths globally. The ensuing side effects brought on by the toxicity of conventional drugs are a challenging problem associated with chemotherapy. It is understandably problematic to deliver chemotherapeutic medications precisely to the affected site of something like the colon in a predictable and dependable manner. Chemotherapy and surgery were the only options available to cancer patients for a long time. The prognosis for CRC has never been good, especially for patients with metastatic cancers. Targeted therapy, a recent optional method, has been successful in extending the overall survival of CRC patients. Following successes with the anti-EGFR (epidermal growth factor receptor) drug cetuximab and the anti-angiogenesis drug bevacizumab, new medications that inhibit a variety of critical pathways and immunological checkpoints are being developed at an unheard-of rate. Guidelines for the recommended targeted drugs are being updated globally based on the growing body of high-quality clinical research. This study provides a summary of the present CRC-targeted medications and their underlying mechanisms, along with a discussion of their shortcomings and potential future possibilities. Keywords: Chemotherapeutic medicines, Bevacizumab, Cetuximab, Colorectal cancer
Authors: Altaf Dar, Mohd, Aslam Hamid Khan
Institution: Chandigarh University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7217825789
